Acta Pharmaceuticals raises $24m for Alzheimer’s therapies
Acta Pharmaceuticals expects to begin a Phase I clinical trial in October 2026 for its lead asset, GSM-779690T.
Drug Development
Transcripta Bio, Mayo Clinic join force on ALS therapies
QCi and INmune Bio partner to study XPro in Alzheimer’s
Charles River partners with Magellan Stem Cells on cell therapy
Pfizer partners with Enodia Therapeutics in $500m drug deal
China’s NMPA clears Foresee’s Camcevi 42 mg for prostate cancer
Southern Research secures NIH funding for drug testing hub
FDA approves Asahi Kasei’s Hovilpri for refractory HSV
